| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITIH4 |
| Uniprot No | Q14624 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 689-930aa |
| 氨基酸序列 | RLAILPASAPPATSNPDPAVSRVMNMKIEETTMTTQTPAPIQAPSAILPLPGQSVERLCVDPRHRQGPVNLLSDPEQGVEVTGQYEREKAGFSWIEVTFKNPLVWVHASPEHVVVTRNRRSSAYKWKETLFSVMPGLKMTMDKTGLLLLSDPDKVTIGLLFWDGRGEGLRLLLRDTDRFSSHVGGTLGQFYQEVLWGSPAASDDGRRTLRVQGNDHSATRERRLDYQEGPPGVEISCWSVEL |
| 预测分子量 | 42.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITIH4重组蛋白的3篇代表性文献的示例(注：以下内容为模拟虚构，仅供参考格式)：
---
1. **文献名称**: *Recombinant ITIH4 Expression and Its Role in Liver Cancer Biomarker Discovery*
**作者**: Zhang L, et al.
**摘要**: 本研究通过哺乳动物细胞表达系统成功制备了重组ITIH4蛋白，并验证其在肝癌患者血清中的表达水平显著升高。实验表明，重组ITIH4可用于开发高灵敏度的ELISA检测方法，为肝癌早期诊断提供潜在生物标志物。
2. **文献名称**: *Structural Characterization of Human ITIH4 Using Recombinant Protein Technology*
**作者**: Müller S, et al.
**摘要**: 利用X射线晶体学解析了重组ITIH4蛋白的三维结构，揭示了其与透明质酸结合的活性位点。结果提示ITIH4可能通过稳定细胞外基质参与组织修复，为研究其病理生理功能提供结构基础。
3. **文献名称**: *ITIH4 Recombinant Protein Modulates Inflammation in Sepsis Models*
**作者**: Chen H, et al.
**摘要**: 通过大肠杆菌表达系统纯化重组ITIH4蛋白，并在小鼠脓毒症模型中验证其抗炎作用。研究发现，外源性ITIH4可抑制TLR4/NF-κB通路，降低促炎因子水平，提示其作为治疗炎症性疾病的潜在药物靶点。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词“Recombinant ITIH4 protein”或“ITIH4 biomarker”获取最新研究。
**Background of ITIH4 Recombinant Protein**
Inter-alpha-trypsin inhibitor heavy chain 4 (ITIH4) is a member of the inter-alpha-trypsin inhibitor (ITI) family, a group of plasma proteins involved in inflammation, extracellular matrix stabilization, and protease regulation. ITIH4. encoded by the *ITIH4* gene, is synthesized primarily in the liver and circulates in blood as part of the ITI complex or in free form. Structurally, it contains two immunoglobulin-like domains and a variable region, facilitating interactions with hyaluronan and other components of the extracellular matrix. ITIH4 plays roles in inflammation modulation, tissue repair, and complement system regulation, though its precise mechanisms remain under investigation.
Recombinant ITIH4 protein is produced using genetic engineering techniques, typically by expressing the *ITIH4* gene in bacterial, yeast, or mammalian cell systems. Mammalian systems (e.g., HEK293 or CHO cells) are preferred for generating post-translationally modified, bioactive forms of the protein. Purification involves affinity chromatography, often leveraging tags like His or FLAG, followed by ion-exchange or size-exclusion chromatography to ensure high purity.
Research on ITIH4 has highlighted its potential as a biomarker for various diseases. Elevated or reduced ITIH4 levels correlate with conditions such as liver cancer, breast cancer, preeclampsia, and sepsis, suggesting diagnostic or prognostic utility. Its involvement in inflammation and cell adhesion also positions it as a therapeutic target. For example, ITIH4 may inhibit tumor metastasis by stabilizing the extracellular matrix or modulate immune responses in autoimmune diseases.
Challenges in studying ITIH4 include its complex interactions with other ITI components and sensitivity to proteolytic cleavage. Additionally, recombinant production must address proper folding and post-translational modifications (e.g., glycosylation) to maintain functionality. Despite these hurdles, ITIH4 remains a promising focus for understanding disease mechanisms and developing clinical applications.
×
